220 related articles for article (PubMed ID: 37534686)
21. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series.
Holbrook K; Lutzky J; Davies MA; Davis JM; Glitza IC; Amaria RN; Diab A; Patel SP; Amin A; Tawbi H
Cancer; 2020 Feb; 126(3):523-530. PubMed ID: 31658370
[TBL] [Abstract][Full Text] [Related]
22. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
Daud A; Tsai K
Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
[TBL] [Abstract][Full Text] [Related]
23. Encorafenib plus binimetinib in patients with
Riely GJ; Ahn MJ; Felip E; Ramalingam SS; Smit EF; Tsao AS; Alcasid A; Usari T; Wissel PS; Wilner KD; Johnson BE
Future Oncol; 2022 Mar; 18(7):781-791. PubMed ID: 34918546
[TBL] [Abstract][Full Text] [Related]
24. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
25. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
Shattuck-Brandt RL; Chen SC; Murray E; Johnson CA; Crandall H; O'Neal JF; Al-Rohil RN; Nebhan CA; Bharti V; Dahlman KB; Ayers GD; Yan C; Kelley MC; Kauffmann RM; Hooks M; Grau A; Johnson DB; Vilgelm AE; Richmond A
Clin Cancer Res; 2020 Jul; 26(14):3803-3818. PubMed ID: 32234759
[TBL] [Abstract][Full Text] [Related]
26. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
[TBL] [Abstract][Full Text] [Related]
27. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
[TBL] [Abstract][Full Text] [Related]
28. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
29. An overview of binimetinib for the treatment of melanoma.
Specenier P
Expert Opin Pharmacother; 2020 May; 21(7):747-754. PubMed ID: 32100585
[TBL] [Abstract][Full Text] [Related]
30. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF
Schreuer M; Jansen Y; Planken S; Chevolet I; Seremet T; Kruse V; Neyns B
Lancet Oncol; 2017 Apr; 18(4):464-472. PubMed ID: 28268064
[TBL] [Abstract][Full Text] [Related]
31. The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma.
Amaral T; Nouri N; Garbe C
Expert Rev Anticancer Ther; 2016 Jul; 16(7):705-15. PubMed ID: 27219630
[TBL] [Abstract][Full Text] [Related]
32. Truth or dare: switching BRAF/MEK inhibitors after acute interstitial nephritis in a patient with metastatic melanoma - A case report and review of the literature.
De Ryck L; Delanghe S; Jacobs C; Fadaei S; Brochez L; Saerens M
Acta Clin Belg; 2023 Jun; 78(3):215-222. PubMed ID: 35996969
[TBL] [Abstract][Full Text] [Related]
33. [Management of toxicities of BRAF inhibitors and MEK inhibitors in advanced melanoma].
Sibaud V; Baric L; Cantagrel A; Di Palma M; Ederhy S; Paques M; Perlemuter G
Bull Cancer; 2021 May; 108(5):528-543. PubMed ID: 33812673
[TBL] [Abstract][Full Text] [Related]
34. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV; Flaherty KT; Stroyakovskiy D; Gogas H; Levchenko E; de Braud F; Larkin J; Garbe C; Jouary T; Hauschild A; Chiarion-Sileni V; Lebbe C; MandalĂ M; Millward M; Arance A; Bondarenko I; Haanen JBAG; Hansson J; Utikal J; Ferraresi V; Mohr P; Probachai V; Schadendorf D; Nathan P; Robert C; Ribas A; Davies MA; Lane SR; Legos JJ; Mookerjee B; Grob JJ
Ann Oncol; 2017 Jul; 28(7):1631-1639. PubMed ID: 28475671
[TBL] [Abstract][Full Text] [Related]
35. Severe colitis in patients with melanoma treated with BRAF/MEK inhibitors.
Carbonnel F; Routier E; Lazure T; Mussini C; Bellanger C; Merklen C; Bejou B; Buisson A; Amiot A; Meyer A; Dong C; Robert C
Aliment Pharmacol Ther; 2023 Apr; 57(7):792-799. PubMed ID: 36578099
[TBL] [Abstract][Full Text] [Related]
36. Edoxaban prevented adverse effects including pyrexia and elevation of D-dimer caused by the combination of BRAF and MEK inhibitors in a patient with BRAF-mutant melanoma.
Mukai K; Kamata M; Miyazaki M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Ishikawa T; Ohnishi T; Tada Y; Tanaka T
J Dermatol; 2021 May; 48(5):707-709. PubMed ID: 33600004
[TBL] [Abstract][Full Text] [Related]
37. A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma
Tarhini AA; Toor K; Chan K; McDermott DF; Mohr P; Larkin J; Hodi FS; Lee CH; Rizzo JI; Johnson H; Moshyk A; Rao S; Kotapati S; Atkins MB
ESMO Open; 2021 Apr; 6(2):100050. PubMed ID: 33556898
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
Li SN; Wan X; Peng LB; Li YM; Li JH
BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848
[TBL] [Abstract][Full Text] [Related]
39. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM; Dumas L; Larkin J
Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
[TBL] [Abstract][Full Text] [Related]
40. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]